ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Slamon, Sherr Win Landon-AACR Prizes

March 7, 2003

New Guidelines Developed For Cooperative Group Grant Review

August 17, 1979

Panel Angered By Unreasonable Senate Committee Demands, Will Seek Meeting With Hatch On Probe

April 24, 1981

NCI CTEP-Approved Trials For the Month of February

February 28, 2014

Editorial: Rumor Mill Fills The Gap When Access Denied

December 16, 1994

FDA Commissioner Says Swifter Drug Approvals, Enforcement Emphasis Characterize ‘Today’s FDA’

January 31, 1992